Site Menu
Buscar Close Search
Buscar Close Search

Publication Spotlights

 

Congratulations on our team's most recent publication achievements!


SIMS training A recent publication on teaching palliative care to neurology residents at UMass in a simulated setting showcases the collaboration between palliative care and neurology in a recent article published in Neurology Journal titled Curriculum Innovations: Enhancing skills in serious illness communication in Neurology Residents Using Simulation: 

Read the article published by UMass Chan News, https://www.umassmed.edu/medicine/research/researchers-in-the-news/palliative-care-and-neurology-collaborate-to-develop-curriculum-that-aims-to-improve-serious-illness-communication-skills-for-neurology-residents/ 

April 2025 

Felicia Chu, first author, of the April 2025 publication in Frontiers in Neurology, titled, Clinician and patient readiness to engage with community health workers at epilepsy care centers

Felicia Chu, last author, of the April 2025 publication in Frontiers in Neurology, titled, A qualitative analysis of clinician perspectives on community health worker integration at epilepsy centers

March 2025

Margaret Owegi and the Neuromuscular Medicine Research Center collaboration in The Healey ALS Platform Trial. Most recently, the trial study published three articles detailing the research findings. 

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | JAMA | JAMA Network 

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | JAMA Neurology | JAMA Network 

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial | Amyotrophic Lateral Sclerosis | JAMA | JAMA Network 

 

Access to the PubMed list of publications

Total: displaying 15 out of 50 results
<<<1234>>>

  • A multicenter, propensity score-matched analysis of functional outcomes and recanalization success with or without Trevo for Medium and distal vessel occlusion

    Wednesday, May 21, 2025
    Author(s): James E Siegler,Manisha Koneru,Hamza Shaikh,Hamza Adel Salim,Basel Musmar,Nimer Adeeb,Vivek Yedavalli,Motaz Daraghma,Kareem El Naamani,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Sherief Ghozy,Luca Scarcia,Benjamin Yq Tan,Jeremy J Heit,Robert W Regenhardt,Rami Z Morsi,Tareq Kass-Hout,Nicholas Vigilante,Nicole M Cancelliere,Joshua D Bernstock,Aymeric Rouchaud,Jens Fiehler,Sunil A Sheth,Muhammed Amir Essibayi,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Xavier Barreau,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Răzvan Alexandru Radu,Thomas R Marotta,Julian Spears,Takahiro Ota,Ashkan Mowla,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,Piers Klein,Mohamad Abdalkader,Thanh N Nguyen,Ricardo Varela,Amanda Baker,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Constantin Hecker,Christoph J Griessenauer,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Illario Tancredi,Tobias D Faizy,Erwah Kalsoum,Boris Lubicz,Aman B Patel,Vitor Mendes Pereira,Jane Khalife,Ankit Rana,Adrien Guenego,Adam A Dmytriw,MAD MT Investigators
    Source: Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
    BackgroundEndovascular therapy (EVT) for stroke due to distal or medium vessel occlusion (DMVO) is safe. Due to the distinct anatomical characteristics of DMVOs, further evaluation of EVT is crucial to determine which devices may yield better outcomes.MethodsA retrospective analysis of adults with DMVO treated in 37 centers (11 countries) was queried. The primary outcome of favorable shift in 90-day modified Rankin Scale (mRS) was compared between patients treated with Trevo versus other devices...

  • RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice

    Sunday, May 11, 2025
    Author(s): Alexandra Weiss,James W Gilbert,Iris Valeria Rivera Flores,Jillian Belgrad,Chantal Ferguson,Elif O Dogan,Nicholas Wightman,Kit Mocarski,Dimas Echeverria,Ashley L Harkins,Ashley Summers,Brianna Bramoto,Nicholas McHugh,Raymond Furgal,Nozomi Yamada,David Cooper,Kathryn Monopoli,Bruno M D C Godinho,Matthew R Hassler,Ken Yamada,Paul Greer,Nils Henninger,Robert H Brown,Anastasia Khvorova
    Source: Molecular therapy : the journal of the American Society of Gene Therapy
    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition, with 20% of familial and 2-3% of sporadic cases linked to mutations in the cytosolic superoxide dismutase (SOD1) gene. Mutant SOD1 protein is toxic to motor neurons, making SOD1 gene suppression a promising approach, supported by preclinical data and the 2023 FDA approval of the GapmeR ASO targeting SOD1, tofersen. Despite the approval of an ASO and the optimism it brings to the field, the pharmacodynamics and...

  • Shared decision-making for multiple sclerosis using the MS-SUPPORT tool: a plain language summary

    Wednesday, May 07, 2025
    Author(s): Nananda F Col,Andrew J Solomon,Enrique Alvarez,Lori Pbert,Carolina Ionete,Idanis Berrios Morales,Jennifer Chester,Christen Kutz,Crystal Iwuchukwu,Terrie Livingston,Vicky Springmann,Hannah Col,Long Ngo
    Source: Neurodegenerative disease management
    No abstract

  • Current Clinical Applications of AAV-mediated Gene Therapy

    Wednesday, May 07, 2025
    Author(s): Barry J Byrne,Kevin M Flanigan,Susan E Matesanz,Richard S Finkel,Megan A Waldrop,Eleonora S D'Ambrosio,Nicholas E Johnson,Barbara K Smith,Carsten Bönnemann,Sean Carrig,Joseph W Rossano,Barry Greenberg,Laura Lalaguna,Enrique Lara-Pezzi,Sub Subramony,Manuela Corti,Claudia Mercado-Rodriguez,Carmen Leon-Astudillo,Rebecca Ahrens-Nicklas,Diana Bharucha-Goebel,Guangping Gao,Dominic J Gessler,Wuh-Liang Hwu,Yin-Hsiu Chien,Ni-Chung Lee,Sanford L Boye,Shannon E Boye,Lindsey A George
    Source: Molecular therapy : the journal of the American Society of Gene Therapy
    Currently, there are an estimated 8,000 genetic disorders that cumulatively affect approximately 10% of the population. Even among the 5% of patients with genetic disease that have treatment options, these therapeutics rarely address the underlying cause of disease but rather focus on managing or modifying symptoms and typically require recurrent, lifelong therapy. A therapeutic approach to genetic disease that in vivo delivers a functional copy of the aberrant gene is an intuitive solution that...

  • Clinician and patient readiness to engage with community health workers at epilepsy care centers

    Wednesday, April 30, 2025
    Author(s): Felicia C Chu,Barbara C Jobst,Anna Murray,Trina Dawson,Christine F Frisard,Barbara Glidden,Sarah J Kaden,Elaine T Kiriakopoulos
    Source: Frontiers in neurology
    CONCLUSION: Despite limited understanding of CHW roles or firsthand experience with CHWs, clinician and patient readiness for integration of CHW was high, with a strong indication that clinicians would refer patients to a CHW and that patients felt the potential for health benefit if provided with assistance from a CHW.

  • Validity and Reliability of Clinical and Patient-Reported Outcomes in Multisystem Proteinopathy 1

    Monday, April 28, 2025
    Author(s): Lindsay N Alfano,Megan A Iammarino,Natalie F Reash,Linda P Lowes,Lindsay Pietruszewski,Kathleen Adderley,Lauren Humphrey,Audrey B Knight,Christopher L Steiner,Melissa A Smith,Zarife Sahenk,Anne M Connolly,Momen Almomen,Eleonora S D'Ambrosio,Nathan Peck,Allison Peck
    Source: Annals of clinical and translational neurology
    OBJECTIVE: Valosin-containing protein (VCP)-associated multisystem proteinopathy 1 (MSP1) is caused by variants in the VCP gene. MSP1 results in various phenotypes including progressive myopathy, Paget's disease of bone, frontotemporal dementia, amyotrophic lateral sclerosis, and parkinsonism, among others. Our study aimed to validate functional clinical outcome assessments (COA) and patient-reported outcomes (PRO) to inform clinical care practices and future clinical trial design. In addition,...

  • KIF5A p.Pro986Leu Risk Variant and Accelerated Progression of Amyotrophic Lateral Sclerosis

    Friday, April 25, 2025
    Author(s): Arianna Manini,Rosario Vasta,Alberto Brusati,Francesco Scheveger,Silvia Peverelli,Alessio Maranzano,Alberto Doretti,Francesco Gentile,Eleonora Colombo,Maura Brunetti,Cristina Moglia,Antonio Canosa,Umberto Manera,Maurizio Grassano,Davide Gentilini,Stefano Messina,Federico Verde,Claudia Morelli,John E Landers,Bryan J Traynor,Adriano Chiò,Vincenzo Silani,Andrea Calvo,Antonia Ratti,Nicola Ticozzi
    Source: Annals of clinical and translational neurology
    This study explored the impact of KIF5A rs113247976 (p.Pro986Leu), a risk allele for amyotrophic lateral sclerosis (ALS), on phenotypic variability in two Italian ALS cohorts (discovery, n = 865; replication, n = 1174). The minor allele (T) frequency was 0.015. No patients were homozygous (TT), allowing comparison between wild type and heterozygous carriers only. Heterozygous carriers showed faster disease progression (ALSFRS-R preslope). Findings were validated across both cohorts. Multiple...

  • A qualitative analysis of clinician perspectives on community health worker integration at epilepsy centers

    Thursday, April 24, 2025
    Author(s): Elaine T Kiriakopoulos,Barbara Jobst,Anna Murray,Carly Sykes,Suzanne Lenz,Trina Dawson,Sarah Kaden,Felicia Chu
    Source: Frontiers in neurology
    INTRODUCTION: Substantial evidence supports community health worker (CHW) interventions lead to improved health outcomes, but health professionals' perceptions of CHW roles and effectiveness may slow integration into care delivery systems. Research on CHWs as members of specialty care teams in clinical settings, especially in the epilepsy field, is limited.

  • Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis

    Wednesday, April 09, 2025
    Author(s): Jiwon Oh,Douglas L Arnold,Bruce A C Cree,Carolina Ionete,Ho Jin Kim,Maria Pia Sormani,Sana Syed,Yixin Chen,Christina R Maxwell,Patrick Benoit,Timothy J Turner,Erik Wallstroem,Heinz Wiendl,Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group
    Source: The New England journal of medicine
    CONCLUSIONS: Tolebrutinib was not superior to teriflunomide in decreasing annualized relapse rates among participants with relapsing multiple sclerosis. (Funded by Sanofi; GEMINI 1 and GEMINI 2 ClinicalTrials.gov numbers, NCT04410978 and NCT04410991, respectively.).

  • New Mouse Lines That Drive Tetracycline-Controlled Gene Expression in a Small Subset of Spinal Cord Dorsal Horn Neurons

    Tuesday, April 08, 2025
    Author(s): Eric Fyrberg,Heather Learnard,Soojin Lee,Yong-Woo Jun,Fen-Biao Gao
    Source: eNeuro
    Mouse lines with tetracycline-controlled gene expression in specific neuronal populations provide valuable tools for studying their development, function, connectivity, and pathology in vivo. Our initial goal was to generate a mouse model that could express amyotrophic lateral sclerosis-associated genes specifically in spinal cord motor neurons under the control of the HB9 promoter. However, HB9-tTA mice unexpectedly direct target gene expression in a small subset of dorsal horn neurons. These...

  • Incidence Trends and Risk of Recurrent Stroke of Cervical Artery Dissections in the United States Between 2005 and 2019

    Wednesday, April 02, 2025
    Author(s): Liqi Shu,Lukas Strelecky,Adam de Havenon,Thanh N Nguyen,Nils Henninger,Zafer Keser,Muhib Khan,James Ernest Siegler,Mary Penckofer,Setareh Salehi Omran,Thalia S Field,Lily Zhou,Han Xiao,Austin Jacobson,Eric D Goldstein,Christoph Stretz,Farhan Khan,Elizabeth Perelstein,Karen Furie,Shadi Yaghi
    Source: Neurology
    BACKGROUND AND OBJECTIVES: Cervical artery dissection (CeAD) is a common cause of acute ischemic stroke (AIS), especially in patients younger than 55 years, but data regarding trends and subsequent AIS risk after CeAD remain scarce. We aimed to determine national trends in CeAD admissions and examine post-CeAD risk of ischemic stroke.

  • Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection

    Thursday, March 27, 2025
    Author(s): Daniel M Mandel,Liqi Shu,Christopher Chang,Naomi Jack,Christopher R Leon Guerrero,Nils Henninger,Jayachandra Muppa,Muhammad Affan,Omair Ul Haq Lodhi,Mirjam R Heldner,Kateryna Antonenko,David Seiffge,Marcel Arnold,Setareh Salehi Omran,Ross Crandall,Evan Lester,Diego Lopez Mena,Antonio Arauz,Ahmad Nehme,Marion Boulanger,Emmanuel Touze,Joao Andre Sousa,Joao Sargento-Freitas,Vasco Barata,Paulo Castro-Chaves,Maria Teresa Brito,Muhib Khan,Dania Mallick,Aaron Rothstein,Ossama Khazaal,Josefin E Kaufman,Stefan T Engelter,Christopher Traenka,Diana Aguiar de Sousa,Mafalda Soares,Sara Rosa,Lily W Zhou,Preet Gandhi,Thalia S Field,Steven Mancini,Issa Metanis,Ronen R Leker,Kelly Pan,Vishnu Dantu,Karl Baumgartner,Tina Burton,Regina von Rennenberg,Christian H Nolte,Richard Choi,Jason MacDonald,Reza Bavarsad Shahripour,Xiaofan Guo,Malik Ghannam,Mohammad Almajali,Edgar A Samaniego,Sebastian Sanchez,Bastien Rioux,Faycal Zine-Eddine,Alexandre Poppe,Ana Catarina Fonseca,Maria Fortuna Baptista,Diana Cruz,Michele Romoli,Giovanna De Marco,Marco Longoni,Zafer Keser,Kim Griffin,Lindsey Kuohn,Jennifer Frontera,Jordan Amar,James Giles,Marialuisa Zedde,Rosario Pascarella,Ilaria Grisendi,Hipolito Nzwalo,David S Liebeskind,Amir Molaie,Annie Cavalier,Wayneho Kam,Brian Mac Grory,Sami Al Kasab,Mohammad Anadani,Kimberly Kicielinski,Ali Eltatawy,Lina Chervak,Roberto Chulluncuy Rivas,Yasmin Aziz,Ekaterina Bakradze,Thanh Lam Tran,Marc Rodrigo Gisbert,Manuel Requena,Faddi Saleh Velez,Jorge Ortiz Gracia,Varsha Muddasani,Adam de Havenon,Venugopalan Y Vishnu,Sridhara Yaddanapudi,Latasha Adams,Abigail Browngoehl,Tamra Ranasinghe,Randy Dunston,Zachary Lynch,Mary Penckofer,James E Siegler,Silvia Mayer,Joshua Willey,Adeel Zubair,Yee Kuang Cheng,Richa Sharma,João Pedro Marto,Vítor Mendes Ferreira,Piers Klein,Thanh N Nguyen,Syed Daniyal Asad,Zoha Sarwat,Anvesh Balabhadra,Shivam Patel,Thais Secchi,Sheila Martins,Gabriel Mantovani,Young Dae Kim,Balaji Krishnaiah,Cheran Elangovan,Sivani Lingam,Abid Quereshi,Sebastian Fridman,Alonso Alvarado,Farid Khasiyev,Guillermo Linares,Marina Mannino,Valeria Terruso,Sofia Vassilopoulou,Vasileios Tentolouris-Piperas,Manuel Martinez Marino,Victor Carrasco Wall,Fransisca Indraswari,Sleiman El Jamal,Shilin Liu,Muhammad Alvi,Farman Ali,Mohammed Sarvath,Rami Z Morsi,Tareq Kass-Hout,Feina Shi,Jinhua Zhang,Dilraj Sokhi,Jamil Said,Newnex Mongare,Alexis Simpkins,Roberto Gomez,Shayak Sen,Mohammad Ghani,Marwa Elnazeir,Han Xiao,Narendra Kala,Farhan Khan,Christoph Stretz,Nahid Mohammadzadeh,Eric Goldstein,Karen Furie,Shadi Yaghi
    Source: Stroke
    CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.

  • Characteristics and Medication Use Patterns of Pregnancies With COVID-19 Ending in Live-Birth in the Sentinel System

    Wednesday, March 26, 2025
    Author(s): Mayura Shinde,Austin Cosgrove,Jennifer G Lyons,Maria E Kempner,Jolene Mosley,David Cole,Emma Hoffman,Elizabeth Messenger-Jones,José J Hernández-Muñoz,Danijela Stojanovic,Benedict H W Wong,Yueqin Zhao,Leyla Sahin,Susan E Andrade,Sengwee Toh,Wei Hua
    Source: Pharmacoepidemiology and drug safety
    CONCLUSIONS: In this retrospective evaluation, selected medication utilization was higher post-COVID-19 among pregnancies with COVID-19, compared to those without COVID-19 and to non-pregnancy episodes with COVID-19. However, the low use of COVID-19-specific medications underscores the need for a safety evaluation of therapies used for COVID-19 management in the pregnant population.

  • In-Hospital Mortality Prediction among Intensive Care Unit Patients with Acute Ischemic Stroke: A Machine Learning Approach

    Tuesday, March 18, 2025
    Author(s): Jack A Cummins,Ben S Gerber,Mayuko Ito Fukunaga,Nils Henninger,Catarina I Kiefe,Feifan Liu
    Source: Health data science
    Background: Acute ischemic stroke is a leading cause of death in the United States. Identifying patients with stroke at high risk of mortality is crucial for timely intervention and optimal resource allocation. This study aims to develop and validate machine learning-based models to predict in-hospital mortality risk for intensive care unit (ICU) patients with acute ischemic stroke and identify important associated factors. Methods: Our data include 3,489 acute ischemic stroke admissions to the...

  • CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial

    Tuesday, March 11, 2025
    Author(s): Writing Committee for the HEALEY ALS Platform Trial,James D Berry,Nicholas J Maragakis,Eric A Macklin,Lori B Chibnik,Melanie Quintana,Benjamin R Saville,Michelle A Detry,Matteo Vestrucci,Joseph Marion,Anna McGlothlin,Elijah W Stommel,Marianne Chase,Lindsay Pothier,Brittney A Harkey,Hong Yu,Alex Sherman,Jeremy Shefner,Meghan Hall,Gale Kittle,Suma Babu,Jinsy Andrews,Derek D'Agostino,Eric Tustison,Erica Scirocco,Elisa Giacomelli,Gustavo Alameda,Eduardo Locatelli,Doreen Ho,Adam Quick,Senda Ajroud-Driss,Jonathan Katz,Daragh Heitzman,Stanley H Appel,Sheetal Shroff,Kevin J Felice,Zachary Simmons,Timothy Miller,Nicholas Olney,Michael D Weiss,Stephen A Goutman,Joseph Americo Fernandes,Omar Jawdat,Margaret Ayo Owegi,Laura Foster,Tuan Vu,Hristelina Ilieva,Daniel S Newman,Ximena Arcila-Londono,Carlayne Jackson,Shafeeq Ladha,Terry Heiman-Patterson,James Caress,Andrea Swenson,Amanda Peltier,Richard Lewis,Dominic Fee,Matthew Elliott,Richard Bedlack,Edward J Kasarskis,Lauren Elman,Jeffrey Rosenfeld,David Walk,Courtney E McIlduff,Paul Twydell,Eufrosina Young,Kristin Johnson,Kourosh Rezania,Namita A Goyal,Jeffrey A Cohen,Michael Benatar,Vovanti Jones,Jonathan Glass,Jaimin Shah,Said R Beydoun,James P Wymer,Lindsay Zilliox,Shakti Nayar,Gary L Pattee,Jennifer Martinez-Thompson,Austin Rynders,Jacob Evan,Jeremy Evan,Alan Hartford,Marjan Sepassi,Karen S Ho,Robert Glanzman,Benjamin Greenberg,Michael T Hotchkin,Sabrina Paganoni,Merit E Cudkowicz,HEALEY ALS Platform Trial Study Group
    Source: JAMA
    CONCLUSIONS AND RELEVANCE: No benefit of CNM-Au8 on ALS disease progression was observed at 24 weeks.
<<<1234>>>